Skip to main content
Erschienen in: Pediatric Nephrology 3/2010

01.03.2010 | Brief Report

A case of minimal change disease in a Fabry patient

verfasst von: Yuri A. Zarate, Larry Patterson, Hong Yin, Robert J. Hopkin

Erschienen in: Pediatric Nephrology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations of the GLA gene and deficiency in α-galactosidase A activity. Glycosphingolipids accumulation causes renal injury that manifests early during childhood as tubular dysfunction and later in adulthood as proteinuria and renal insufficiency. Nephrotic syndrome as the first evidence of Fabry-related kidney damage is rare. We report the case of a teenager with known Fabry disease and normal renal function who developed acute nephrotic syndrome. He was found to have typical glycosphingolipids accumulation with no other findings suggestive of alternative causes of nephrotic syndrome on kidney biopsy. After treatment with enzyme replacement therapy and oral steroids, he went into complete remission from nephrotic syndrome, a response that is atypical for Fabry disease patients who develop heavy proteinuria as a result of longstanding disease and chronic renal injury. The nephrotic syndrome in this patient appears to have developed secondary to minimal change disease. We recommend considering immunotherapy in addition to enzyme replacement therapy in those patients with confirmed Fabry disease and acute nephrotic syndrome with clinical and microscopic findings suggestive of minimal change disease.
Literatur
2.
Zurück zum Zitat Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMed Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMed
3.
Zurück zum Zitat Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92CrossRefPubMed Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92CrossRefPubMed
4.
Zurück zum Zitat Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932 Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932
5.
Zurück zum Zitat Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355 Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355
6.
Zurück zum Zitat Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555 Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555
7.
Zurück zum Zitat Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138 Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138
8.
Zurück zum Zitat Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:e82–e89 Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:e82–e89
9.
Zurück zum Zitat Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607CrossRefPubMed Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607CrossRefPubMed
10.
Zurück zum Zitat Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T (1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1303–1307PubMed Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T (1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1303–1307PubMed
11.
Zurück zum Zitat Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71–75 Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71–75
12.
Zurück zum Zitat Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B (2005) Fabry nephropathy in a female with superposed IgA glomerulonephritis. G Ital Nefrol 22:385–389 Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B (2005) Fabry nephropathy in a female with superposed IgA glomerulonephritis. G Ital Nefrol 22:385–389
13.
Zurück zum Zitat Shimazu K, Tomiyoshi Y, Aoki S, Sakemi T, Sugihara H (2002) Crescentic glomerulonephritis in a patient with heterozygous Fabry’s disease. Nephron 92:456–458CrossRefPubMed Shimazu K, Tomiyoshi Y, Aoki S, Sakemi T, Sugihara H (2002) Crescentic glomerulonephritis in a patient with heterozygous Fabry’s disease. Nephron 92:456–458CrossRefPubMed
14.
Zurück zum Zitat Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55:73–79PubMed Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55:73–79PubMed
15.
Zurück zum Zitat Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMed Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMed
16.
Zurück zum Zitat Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946 Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946
17.
Zurück zum Zitat Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617CrossRefPubMed Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617CrossRefPubMed
18.
Zurück zum Zitat Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19:1295–1301CrossRefPubMed Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19:1295–1301CrossRefPubMed
19.
Zurück zum Zitat Saha TC, Singh H (2006) Minimal change disease: a review. South Med J 99:1264–1270PubMed Saha TC, Singh H (2006) Minimal change disease: a review. South Med J 99:1264–1270PubMed
20.
Zurück zum Zitat Anochie I, Eke F, Okpere A (2006) Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 98:1977–1981PubMed Anochie I, Eke F, Okpere A (2006) Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 98:1977–1981PubMed
Metadaten
Titel
A case of minimal change disease in a Fabry patient
verfasst von
Yuri A. Zarate
Larry Patterson
Hong Yin
Robert J. Hopkin
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 3/2010
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-009-1353-0

Weitere Artikel der Ausgabe 3/2010

Pediatric Nephrology 3/2010 Zur Ausgabe

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.